I am honored to continue my tenure as Editor in Chief of Oncology Data Advisor in 2023. The last year was a thrill for me, as the post afforded me a front-row seat to lectures, panel discussions, and podcasts from some of the most respected names in our field. I can assure you that what we have planned for 2023 is even more ambitious with multiple interview series, long-form essays, and oncology-focused podcasts available nowhere else.
I am thrilled to announce that I will be staying on as Editor in Chief of Oncology Data Advisor for at least another year. It gives me such great joy to work with such an accomplished group of experts in oncology, as well as with an extremely professional core of editors headed up by Keira Smith. We have grand plans for 2023. In the meantime, please avail yourselves of some of the best commentary in oncology today. I want to especially recommend two of our offerings that have recently hit the we...
It's been a busy three months here at Oncology Data Advisor (ODA) since I last banged out an "Editor's Notes." One of the highlights was ODA's presence at the American Society of Clinical Oncology (ASCO) Annual Meeting. Many researchers spoke on camera with us about the work they were presenting at the meeting, and visibility for the website increased tremendously. It was a rousing success. I remain incredibly proud of all the hard work our staff does every day to bring the cutting edge of clini...
From my perch atop the masthead at Oncology Data Advisor, I am awed by the dozens of oncology professionals who give freely of their time and expertise to inform our readership of the latest in their respective areas. Their efforts are what make ODA a premier online resource for all things in this ever-evolving field. My heartfelt thanks go to these wonderful colleagues without whom we would cease to be a publication. In this month's Editor's Letter, I would like to highlight a few of the outsta...
It is my pleasure to assume the post of Editor in Chief of Oncology Data Advisor for 2022. One of the perks of this role is the opportunity to speak directly to you, the readership, about everything we are up to here. Not only do we strive to give you trenchant summaries of the latest and most relevant oncology treatment breakthroughs in print, podcast, and video formats, but we also aim to give you insights into where our experts believe oncology is headed and what hurdles need to be cleared be...